Dr. Harbour is Professor and Chair of the Department of Ophthalmology at UT Southwestern Medical Center. He specializes in ocular oncology.
Dr. Harbour earned his medical degree at Johns Hopkins University and completed a residency in ophthalmology at the Wills Eye Hospital of Thomas Jefferson University. He received advanced training through a fellowship in vitreoretinal diseases and surgery at the Bascom Palmer Eye Institute of the University of Miami, a fellowship in ocular oncology at the University of California, San Francisco, and research training in molecular oncology at Washington University in St. Louis.
Certified by the American Board of Ophthalmology, he joined the UT Southwestern faculty in 2021.
Previously, Dr. Harbour held the Dr. Mark J. Daily, M.D., Endowed Chair at the Bascom Palmer Eye Institute, where he also served as Director of Ocular Oncology and Vice Chair for Translational Research. He also served as Associate Director for Basic Science at the Sylvester Comprehensive Cancer Center of the University of Miami.
Dr. Harbour’s clinical interests focus on ocular tumors such as uveal melanoma, retinoblastoma, and lymphoma. He has trained many residents and fellows and pioneered new surgical methods in fine needle biopsy, laser treatment, and brachytherapy of ocular tumors. He also has been awarded patents for innovations in genetic prognostic testing for uveal melanoma.
His research interests include the use of genetic and genomic technologies to better understand, diagnose, and treat eye cancers. His team discovered three of the most important genomic drivers of metastasis in uveal melanoma, as well as key genomic events in retinoblastoma. His contributions to the field have been recognized by the Association for Research in Vision and Ophthalmology’s Cogan Award and the Macula Society’s Paul Henkind and Rosenthal Awards, among many others.
Dr. Harbour has delivered more than 300 invited scientific lectures and published more than 200 peer-reviewed scientific articles and book chapters.
He is an Associate Editor for Melanoma Research and has served on the editorial boards of Archives of Ophthalmology, Translational Vision Science & Technology, Melanoma Management, Expert Review of Ophthalmology, and Faculty of 1000.
Dr. Harbour is a member of numerous professional organizations, including the Association of American Physicians, American Academy of Ophthalmology, American Association for Cancer Research, and American Association of Ophthalmic Oncologists and Pathologists, and he is the founder of the Collaborative Ocular Oncology Group.
L. to r.: Mithalesh Singh, Ph.D. (Postdoc); Mahsa Sorouri, Ph.D. (Lab Manager); J. William Harbour, M.D.; and Jie Han, M.S. (Research Scientist)
Over the past two decades, the Harbour Laboratory has made great strides in understanding uveal melanoma, the most common primary cancer of the eye. The lab found that uveal melanomas can be divided into two basic forms, based on gene expression profile, mutation status, and chromosomal alterations. Class 1 uveal melanomas have low metastatic risk, whereas class 2 uveal melanomas have high metastatic risk. Based on this discovery, the lab developed a clinical prognostic test based on a 15-gene signature that has been prospectively validated in multiple studies and is currently the standard of care for precision medicine in this cancer type. Further, the lab discovered that mutational inactivation of the tumor suppressor BAP1 accounts for the class 2 uveal melanoma tumor type, as well as a novel BAP1 familial cancer syndrome, which is transmitted in an autosomal dominant fashion and can include uveal and cutaneous melanoma, mesothelioma, renal cell carcinoma, meningioma, and other cancer types.
Recently, the lab discovered that the cancer-testis antigen PRAME can be aberrantly expressed in uveal melanoma, representing an independent prognostic factor in both class 1 and class 2 uveal melanomas. Further work in the lab has disclosed a functional role for PRAME in chromosomal instability, aneuploidy, and tumor progression.
The Harbour Laboratory has established tumor samples and cell lines from a large number of primary human retinoblastoma samples and has undertaken an unprecedented scope and depth of genomic analysis that has disclosed a new understanding of retinoblastoma progression. The lab discovered ESRRG as one of the key drivers of retinoblastoma progression. This estrogen-related orphan receptor plays an essential role in retinal development, hypoxic adaptation, and retinoblastoma progression.
Major research directions in the lab include:
Multiregional genetic evolution of metastatic uveal melanoma.
Rodriguez DA, Yang J, Durante MA, Shoushtari AN, Moschos SJ, Wrzeszczynski KO, Harbour JW, Carvajal RD, 2021 Aug NPJ Genom Med 1 6 70Impact of Genetic Ancestry on Prognostic Biomarkers in Uveal Melanoma.
Rodriguez DA, Sanchez MI, Decatur CL, Correa ZM, Martin ER, Harbour JW, 2020 Oct Cancers (Basel) 11 12Biological Mechanisms and Clinical Significance of BAP1 Mutations in Human Cancer.
Carbone M, Harbour JW, Brugarolas J, Bononi A, Pagano I, Dey A, Krausz T, Pass HI, Yang H, Gaudino G, 2020 08 Cancer Discov 8 10 1103-1120Single-cell analysis reveals new evolutionary complexity in uveal melanoma.
Durante MA, Rodriguez DA, Kurtenbach S, Kuznetsov JN, Sanchez MI, Decatur CL, Snyder H, Feun LG, Livingstone AS, Harbour JW, 2020 01 Nat Commun 1 11 496Genomic evolution of uveal melanoma arising in ocular melanocytosis.
Durante MA, Field MG, Sanchez MI, Covington KR, Decatur CL, Dubovy SR, Harbour JW, 2019 08 Cold Spring Harb Mol Case Stud 4 5Punctuated evolution of canonical genomic aberrations in uveal melanoma.
Field MG, Durante MA, Anbunathan H, Cai LZ, Decatur CL, Bowcock AM, Kurtenbach S, Harbour JW, 2018 01 Nat Commun 1 9 116PRAME as an Independent Biomarker for Metastasis in Uveal Melanoma.
Field MG, Decatur CL, Kurtenbach S, Gezgin G, van der Velden PA, Jager MJ, Kozak KN, Harbour JW, 2016 Mar Clin Cancer Res 5 22 1234-42Recurrent mutations at codon 625 of the splicing factor SF3B1 in uveal melanoma.
Harbour JW, Roberson ED, Anbunathan H, Onken MD, Worley LA, Bowcock AM, 2013 Feb Nat Genet 2 45 133-5HDAC11 activity contributes to MEK inhibitor escape in uveal melanoma.
Sriramareddy SN, Faião-Flores F, Emmons MF, Saha B, Chellappan S, Wyatt C, Smalley I, Licht JD, Durante MA, Harbour JW, Smalley KSM, 2022 Mar Cancer Gene TherPyruvate dehydrogenase inactivation causes glycolytic phenotype in BAP1 mutant uveal melanoma.
Han A, Chua V, Baqai U, Purwin TJ, Bechtel N, Hunter E, Tiago M, Seifert E, Speicher DW, Schug ZT, Harbour JW, Aplin AE, 2022 Jan OncogeneStructural Protein Analysis of Driver Gene Mutations in Conjunctival Melanoma.
Djulbegovic MB, Uversky VN, Harbour JW, Galor A, Karp CL, 2021 Oct Genes (Basel) 10 12Functional impact of titin (TTN) mutations in ocular surface squamous neoplasia.
Djulbegovic MB, Uversky VN, Karp CL, Harbour JW, 2021 Nov Int J Biol MacromolComprehensive assessment of the effect of eye plaque tilt on tumor dosimetry.
Studenski MT, Markoe A, Samuels SE, Correa ZM, Bossart E, Harbour JW, 2021 Jun BrachytherapyIris metastasis from breast cancer successfully treated with Abemaciclib and Letrozole.
Goduni L, Ashkenazy N, Hansen E, Soyano-Muller A, Correa ZM, Harbour JW, 2021 Jun Retin Cases Brief RepUphyloplot2: visualizing phylogenetic trees from single-cell RNA-seq data.
Kurtenbach S, Cruz AM, Rodriguez DA, Durante MA, Harbour JW, 2021 Jun BMC Genomics 1 22 419Therapeutic Escape in Gaq-mutant Uveal Melanoma: It's a FAK.
Harbour JW, 2021 Jun Clin Cancer Res 11 27 2967-2969Secondary Glaucoma Associated with Intraocular Metastatic Cutaneous Melanoma.
Greenfield JA, Rowlands M, Harbour JW, 2021 Jul Ophthalmol GlaucomaThe AMP-dependent kinase pathway is upregulated in BAP1 mutant uveal melanoma.
Chua V, Han A, Bechtel N, Purwin TJ, Hunter E, Liao C, Harbour JW, Aplin AE, 2021 Aug Pigment Cell Melanoma ResKinetic Characterization of ASXL1/2-Mediated Allosteric Regulation of the BAP1 Deubiquitinase.
Peng H, Cassel J, McCracken DS, Prokop JW, Sementino E, Cheung M, Collop PR, Polo A, Joshi S, Mandell JP, Ayyanathan K, Hinds D, Malkowicz SB, Harbour JW, Bowcock AM, Salvino J, Kennedy EJ, Testa JR, Rauscher FJ, 2021 07 Mol Cancer Res 7 19 1099-1112Multimodal Imaging in the Diagnosis of Exophytic Juxtapapillary Retinal Capillary Hemangioblastoma.
Russell JF, Villegas VM, Schwartz SG, Weng CY, Davis JL, Flynn HW, Harbour JW, 2021 05 Am J Ophthalmol 225 128-136PieParty: visualizing cells from scRNA-seq data as pie charts.
Kurtenbach S, Dollar JJ, Cruz AM, Durante MA, Decatur CL, Harbour JW, 2021 05 Life Sci Alliance 5 4Influence of tumor shape and location in eye plaque brachytherapy dosimetry.
Studenski MT, Patel NV, Markoe A, Harbour JW, Samuels SE, 2020 Mar - Apr Brachytherapy 2 19 249-254Bilateral uveitis associated with nivolumab therapy for metastatic non-small cell lung cancer.
Dermarkarian CR, Patel NA, Villegas VM, Harbour JW, 2020 Jun Am J Ophthalmol Case Rep 18 100691A novel cardiomyogenic role for Isl1+ neural crest cells in the inflow tract.
Hatzistergos KE, Durante MA, Valasaki K, Wanschel ACBA, Harbour JW, Hare JM, 2020 Dec Sci Adv 49 6Global Retinoblastoma Presentation and Analysis by National Income Level.
Fabian ID, Abdallah E, Abdullahi SU, Abdulqader RA, Adamou Boubacar S, Ademola-Popoola DS, Adio A, Afshar AR, Aggarwal P, Aghaji AE, Ahmad A, Akib MNR, Al Harby L, Al Ani MH, Alakbarova A, Portabella SA, Al-Badri SAF, Alcasabas APA, Al-Dahmash SA, Alejos A, Alemany-Rubio E, Alfa Bio AI, Alfonso Carreras Y, Al-Haddad C, Al-Hussaini HHY, Ali AM, Alia DB, Al-Jadiry MF, Al-Jumaily U, Alkatan HM, All-Eriksson C, Al-Mafrachi AARM, Almeida AA, Alsawidi KM, Al-Shaheen AASM, Al-Shammary EH, Amiruddin PO, Antonino R, Astbury NJ, Atalay HT, Atchaneeyasakul LO, Atsiaya R, Attaseth T, Aung TH, Ayala S, Baizakova B, Balaguer J, Balayeva R, Balwierz W, Barranco H, Bascaran C, Beck Popovic M, Benavides R, Benmiloud S, Bennani Guebessi N, Berete RC, Berry JL, Bhaduri A, Bhat S, Biddulph SJ, Biewald EM, Bobrova N, Boehme M, Boldt HC, Bonanomi MTBC, Bornfeld N, Bouda GC, Bouguila H, Boumedane A, Brennan RC, Brichard BG, Buaboonnam J, Calderón-Sotelo P, Calle Jara DA, Camuglia JE, Cano MR, Capra M, Cassoux N, Castela G, Castillo L, Català-Mora J, Chantada GL, Chaudhry S, Chaugule SS, Chauhan A, Chawla B, Chernodrinska VS, Chiwanga FS, Chuluunbat T, Cieslik K, Cockcroft RL, Comsa C, Correa ZM, Correa Llano MG, Corson TW, Cowan-Lyn KE, Csóka M, Cui X, Da Gama IV, Dangboon W, Das A, Das S, Davanzo JM, Davidson A, De Potter P, Delgado KQ, Demirci H, Desjardins L, Diaz Coronado RY, Dimaras H, Dodgshun AJ, Donaldson C, Donato Macedo CR, Dragomir MD, Du Y, Du Bruyn M, Edison KS, Eka Sutyawan IW, El Kettani A, Elbahi AM, Elder JE, Elgalaly D, Elhaddad AM, Elhassan MMA, Elzembely MM, Essuman VA, Evina TGA, Fadoo Z, Fandiño AC, Faranoush M, Fasina O, Fernández DDPG, Fernández-Teijeiro A, Foster A, Frenkel S, Fu LD, Fuentes-Alabi SL, Gallie BL, Gandiwa M, Garcia JL, García Aldana D, Gassant PY, Geel JA, Ghassemi F, Girón AV, Gizachew Z, Goenz MA, Gold AS, Goldberg-Lavid M, Gole GA, Gomel N, Gonzalez E, Gonzalez Perez G, González-Rodríguez L, Garcia Pacheco HN, Graells J, Green L, Gregersen PA, Grigorovski NDAK, Guedenon KM, Gunasekera DS, Gündüz AK, Gupta H, Gupta S, Hadjistilianou T, Hamel P, Hamid SA, Hamzah N, Hansen ED, Harbour JW, Hartnett ME, Hasanreisoglu M, Hassan S, Hassan S, Hederova S, Hernandez J, Hernandez LMC, Hessissen L, Hordofa DF, Huang LC, Hubbard GB, Hummlen M, Husakova K, Hussein Al-Janabi AN, Ida R, Ilic VR, Jairaj V, Jeeva I, Jenkinson H, Ji X, Jo DH, Johnson KP, Johnson WJ, Jones MM, Kabesha TBA, Kabore RL, Kaliki S, Kalinaki A, Kantar M, Kao LY, Kardava T, Kebudi R, Kepak T, Keren-Froim N, Khan ZJ, Khaqan HA, Khauv P, Kheir WJ, Khetan V, Khodabande A, Khotenashvili Z, Kim JW, Kim JH, Kiratli H, Kivelä TT, Klett A, Komba Palet JEK, Krivaitiene D, Kruger M, Kulvichit K, Kuntorini MW, Kyara A, Lachmann ES, Lam CPS, Lam GC, Larson SA, Latinovic S, Laurenti KD, Le BHA, Lecuona K, Leverant AA, Li C, Limbu B, Long QB, López JP, Lukamba RM, Lumbroso L, Luna-Fineman S, Lutfi D, Lysytsia L, Magrath GN, Mahajan A, Majeed AR, Maka E, Makan M, Makimbetov EK, Manda C, Martín Begue N, Mason L, Mason JO, Matende IO, Materin M, Mattosinho CCDS, Matua M, Mayet I, Mbumba FB, McKenzie JD, Medina-Sanson A, Mehrvar A, Mengesha AA, Menon V, Mercado GJVD, Mets MB, Midena E, Mishra DKC, Mndeme FG, Mohamedani AA, Mohammad MT, Moll AC, Montero MM, Morales RA, Moreira C, Mruthyunjaya P, Msina MS, Msukwa G, Mudaliar SS, Muma KI, Munier FL, Murgoi G, Murray TG, Musa KO, Mushtaq A, Mustak H, Muyen OM, Naidu G, Nair AG, Naumenko L, Ndoye Roth PA, Nency YM, Neroev V, Ngo H, Nieves RM, Nikitovic M, Nkanga ED, Nkumbe H, Nuruddin M, Nyaywa M, Obono-Obiang G, Oguego NC, Olechowski A, Oliver SCN, Osei-Bonsu P, Ossandon D, Paez-Escamilla MA, Pagarra H, Painter SL, Paintsil V, Paiva L, Pal BP, Palanivelu MS, Papyan R, Parrozzani R, Parulekar M, Pascual Morales CR, Paton KE, Pawinska-Wasikowska K, Pe'er J, Peña A, Peric S, Pham CTM, Philbert R, Plager DA, Pochop P, Polania RA, Polyakov VG, Pompe MT, Pons JJ, Prat D, Prom V, Purwanto I, Qadir AO, Qayyum S, Qian J, Rahman A, Rahman S, Rahmat J, Rajkarnikar P, Ramanjulu R, Ramasubramanian A, Ramirez-Ortiz MA, Raobela L, Rashid R, Reddy MA, Reich E, Renner LA, Reynders D, Ribadu D, Riheia MM, Ritter-Sovinz P, Rojanaporn D, Romero L, Roy SR, Saab RH, Saakyan S, Sabhan AH, Sagoo MS, Said AMA, Saiju R, Salas B, San Román Pacheco S, Sánchez GL, Sayalith P, Scanlan TA, Schefler AC, Schoeman J, Sedaghat A, Seregard S, Seth R, Shah AS, Shakoor SA, Sharma MK, Sherief ST, Shetye NG, Shields CL, Siddiqui SN, Sidi Cheikh S, Silva S, Singh AD, Singh N, Singh U, Singha P, Sitorus RS, Skalet AH, Soebagjo HD, Sorochynska T, Ssali G, Stacey AW, Staffieri SE, Stahl ED, Stathopoulos C, Stirn Kranjc B, Stones DK, Strahlendorf C, Suarez MEC, Sultana S, Sun X, Sundy M, Superstein R, Supriyadi E, Surukrattanaskul S, Suzuki S, Svojgr K, Sylla F, Tamamyan G, Tan D, Tandili A, Tarrillo Leiva FF, Tashvighi M, Tateshi B, Tehuteru ES, Teixeira LF, Teh KH, Theophile T, Toledano H, Trang DL, Traoré F, Trichaiyaporn S, Tuncer S, Tyau-Tyau H, Umar AB, Unal E, Uner OE, Urbak SF, Ushakova TL, Usmanov RH, Valeina S, van Hoefen Wijsard M, Varadisai A, Vasquez L, Vaughan LO, Veleva-Krasteva NV, Verma N, Victor AA, Viksnins M, Villacís Chafla EG, Vishnevskia-Dai V, Vora T, Wachtel AE, Wackernagel W, Waddell K, Wade PD, Wali AH, Wang YZ, Weiss A, Wilson MW, Wime ADC, Wiwatwongwana A, Wiwatwongwana D, Wolley Dod C, Wongwai P, Xiang D, Xiao Y, Yam JC, Yang H, Yanga JM, Yaqub MA, Yarovaya VA, Yarovoy AA, Ye H, Yousef YA, Yuliawati P, Zapata López AM, Zein E, Zhang C, Zhang Y, Zhao J, Zheng X, Zhilyaeva K, Zia N, Ziko OAO, Zondervan M, Bowman R, 2020 05 JAMA Oncol 5 6 685-695Decitabine limits escape from MEK inhibition in uveal melanoma.
Gonçalves J, Emmons MF, Faião-Flores F, Aplin AE, Harbour JW, Licht JD, Wink MR, Smalley KSM, 2020 05 Pigment Cell Melanoma Res 3 33 507-514Single-cell analysis of olfactory neurogenesis and differentiation in adult humans.
Durante MA, Kurtenbach S, Sargi ZB, Harbour JW, Choi R, Kurtenbach S, Goss GM, Matsunami H, Goldstein BJ, 2020 03 Nat Neurosci 3 23 323-326Vitreoretinal lymphoma followed by systemic diffuse large B cell lymphoma.
Fan KC, Tran KD, Harbour JW, Dubovy SA, Patel NA, Albini TA, 2019 Jun J Ophthalmic Inflamm Infect 1 9 11HDAC Inhibition Enhances the In Vivo Efficacy of MEK Inhibitor Therapy in Uveal Melanoma.
Faião-Flores F, Emmons MF, Durante MA, Kinose F, Saha B, Fang B, Koomen JM, Chellappan SP, Maria-Engler SS, Rix U, Licht JD, Harbour JW, Smalley KSM, 2019 09 Clin Cancer Res 18 25 5686-5701An Eight-Year-Old Girl Presents With Two Weeks of Vision Loss and Nightly Headaches.
Scott NL, Tran KD, Cernichiaro-Espinosa LA, Russell JF, Hinkle JW, Harbour JW, Dubovy SR, Berrocal AM, 2019 05 Ophthalmic Surg Lasers Imaging Retina 5 50 314-317Persistent fetal vasculature presenting with axial elongation and platyphakia.
Lin J, Paez-Escamilla M, Teira LE, Fallas B, Harbour JW, 2019 02 J AAPOS 1 23 51-53Follow the nevus: the cost-utility of monitoring for growth of choroidal nevi.
Barsam AS, Gibbons A, McClellan AJ, Harbour JW, Smiddy WE, 2019 Int J Ophthalmol 9 12 1456-1464Drug and disease signature integration identifies synergistic combinations in glioblastoma.
Stathias V, Jermakowicz AM, Maloof ME, Forlin M, Walters W, Suter RK, Durante MA, Williams SL, Harbour JW, Volmar CH, Lyons NJ, Wahlestedt C, Graham RM, Ivan ME, Komotar RJ, Sarkaria JN, Subramanian A, Golub TR, Schürer SC, Ayad NG, 2018 12 Nat Commun 1 9 5315Comprehensive Study of the Clinical Phenotype of Germline BAP1 Variant-Carrying Families Worldwide.
Walpole S, Pritchard AL, Cebulla CM, Pilarski R, Stautberg M, Davidorf FH, de la Fouchardière A, Cabaret O, Golmard L, Stoppa-Lyonnet D, Garfield E, Njauw CN, Cheung M, Turunen JA, Repo P, Järvinen RS, van Doorn R, Jager MJ, Luyten GPM, Marinkovic M, Chau C, Potrony M, Höiom V, Helgadottir H, Pastorino L, Bruno W, Andreotti V, Dalmasso B, Ciccarese G, Queirolo P, Mastracci L, Wadt K, Kiilgaard JF, Speicher MR, van Poppelen N, Kilic E, Al-Jamal RT, Dianzani I, Betti M, Bergmann C, Santagata S, Dahiya S, Taibjee S, Burke J, Poplawski N, O'Shea SJ, Newton-Bishop J, Adlard J, Adams DJ, Lane AM, Kim I, Klebe S, Racher H, Harbour JW, Nickerson ML, Murali R, Palmer JM, Howlie M, Symmons J, Hamilton H, Warrier S, Glasson W, Johansson P, Robles-Espinoza CD, Ossio R, de Klein A, Puig S, Ghiorzo P, Nielsen M, Kivelä TT, Tsao H, Testa JR, Gerami P, Stern MH, Paillerets BB, Abdel-Rahman MH, Hayward NK, 2018 12 J Natl Cancer Inst 12 110 1328-1341Reduced BAP1 activity prevents ASXL1 truncation-driven myeloid malignancy in vivo.
Guo Y, Yang H, Chen S, Zhang P, Li R, Nimer SD, Harbour JW, Xu M, Yang FC, 2018 08 Leukemia 8 32 1834-1837Gain of function of ASXL1 truncating protein in the pathogenesis of myeloid malignancies.
Yang H, Kurtenbach S, Guo Y, Lohse I, Durante MA, Li J, Li Z, Al-Ali H, Li L, Chen Z, Field MG, Zhang P, Chen S, Yamamoto S, Li Z, Zhou Y, Nimer SD, Harbour JW, Wahlestedt C, Xu M, Yang FC, 2018 01 Blood 3 131 328-341Intracameral Topotecan Hydrochloride for Anterior Chamber Seeding of Retinoblastoma.
Paez-Escamilla M, Bagheri N, Teira LE, Corrales-Medina FF, Harbour W, 2017 Dec JAMA Ophthalmol 12 135 1453-1454Molecular Characteristics of Conjunctival Melanoma Using Whole-Exome Sequencing.
Swaminathan SS, Field MG, Sant D, Wang G, Galor A, Dubovy SR, Harbour JW, Karp CL, 2017 12 JAMA Ophthalmol 12 135 1434-1437Multimodal Imaging of Astrocytic Hamartomas Associated With Tuberous Sclerosis.
Schwartz SG, Harbour JW, 2017 09 Ophthalmic Surg Lasers Imaging Retina 9 48 756-758PRAME as a Potential Target for Immunotherapy in Metastatic Uveal Melanoma.
Gezgin G, Luk SJ, Cao J, Dogrusöz M, van der Steen DM, Hagedoorn RS, Krijgsman D, van der Velden PA, Field MG, Luyten GPM, Szuhai K, Harbour JW, Jordanova ES, Heemskerk MHM, Jager MJ, 2017 06 JAMA Ophthalmol 6 135 541-549An international survey of classification and treatment choices for group D retinoblastoma.
Scelfo C, Francis JH, Khetan V, Jenkins T, Marr B, Abramson DH, Shields CL, Pe'er J, Munier F, Berry J, Harbour JW, Yarovoy A, Lucena E, Murray TG, Bhagia P, Paysse E, Tuncer S, Chantada GL, Moll AC, Ushakova T, Plager DA, Ziyovuddin I, Leal CA, Materin MA, Ji XD, Cursino JW, Polania R, Kiratli H, All-Ericsson C, Kebudi R, Honavar SG, Vishnevskia-Dai V, Epelman S, Daniels AB, Ling JD, Traore F, Ramirez-Ortiz MA, 2017 Int J Ophthalmol 6 10 961-967Uveal and Conjunctival Melanoma: Close Together-but Only Distantly Related.
Harbour JW, 2016 Jan Oncology (Williston Park) 1 30 44, 48Driver Mutations in Uveal Melanoma: Associations With Gene Expression Profile and Patient Outcomes.
Decatur CL, Ong E, Garg N, Anbunathan H, Bowcock AM, Field MG, Harbour JW, 2016 07 JAMA Ophthalmol 7 134 728-33ARF6 Is an Actionable Node that Orchestrates Oncogenic GNAQ Signaling in Uveal Melanoma.
Yoo JH, Shi DS, Grossmann AH, Sorensen LK, Tong Z, Mleynek TM, Rogers A, Zhu W, Richards JR, Winter JM, Zhu J, Dunn C, Bajji A, Shenderovich M, Mueller AL, Woodman SE, Harbour JW, Thomas KR, Odelberg SJ, Ostanin K, Li DY, 2016 06 Cancer Cell 6 29 889-904Gene expression profiling and regression rate of irradiated uveal melanomas.
Rao RC, Khan M, Badiyan SN, Harbour JW, 2015 Mar Ophthalmic Surg Lasers Imaging Retina 3 46 333-7Skewed expression of the genes encoding epigenetic modifiers in high-risk uveal melanoma.
Herlihy N, Dogrusöz M, van Essen TH, Harbour JW, van der Velden PA, van Eggermond MC, Haasnoot GW, van den Elsen PJ, Jager MJ, 2015 Jan Invest Ophthalmol Vis Sci 3 56 1447-58Serous macular detachment following a systemic corticosteroid injection.
Weng CY, Harbour JW, 2015 Apr JAMA Ophthalmol 4 133 473-4Epigenetic reprogramming of melanoma cells by vitamin C treatment.
Gustafson CB, Yang C, Dickson KM, Shao H, Van Booven D, Harbour JW, Liu ZJ, Wang G, 2015 Clin Epigenetics 7 51EMT-associated factors promote invasive properties of uveal melanoma cells.
Asnaghi L, Gezgin G, Tripathy A, Handa JT, Merbs SL, van der Velden PA, Jager MJ, Harbour JW, Eberhart CG, 2015 Mol Vis 21 919-29Combined PKC and MEK inhibition for treating metastatic uveal melanoma.
Sagoo MS, Harbour JW, Stebbing J, Bowcock AM, 2014 Sep Oncogene 39 33 4722-3Distinguishing torpedo maculopathy from similar lesions of the posterior segment.
Villegas VM, Schwartz SG, Flynn HW, Capó H, Berrocal AM, Murray TG, Harbour JW, 2014 May-Jun Ophthalmic Surg Lasers Imaging Retina 3 45 222-6Recent developments in prognostic and predictive testing in uveal melanoma.
Field MG, Harbour JW, 2014 May Curr Opin Ophthalmol 3 25 234-9GNAQ/11 mutations in uveal melanoma: is YAP the key to targeted therapy?
Field MG, Harbour JW, 2014 Jun Cancer Cell 6 25 714-5A molecular revolution in uveal melanoma: implications for patient care and targeted therapy.
Harbour JW, Chao DL, 2014 Jun Ophthalmology 6 121 1281-8Prognostic parameters in uveal melanoma and their association with BAP1 expression.
van Essen TH, van Pelt SI, Versluis M, Bronkhorst IH, van Duinen SG, Marinkovic M, Kroes WG, Ruivenkamp CA, Shukla S, de Klein A, Kiliç E, Harbour JW, Luyten GP, van der Velden PA, Verdijk RM, Jager MJ, 2014 Dec Br J Ophthalmol 12 98 1738-43Molecular testing prognostic of low risk in epithelioid uveal melanoma in a child.
Dimaras H, Parulekar MV, Kwok G, Simpson ER, Ali A, Halliday W, Shago M, Harbour JW, Héon E, Gallie BL, Chan HS, 2013 Mar Br J Ophthalmol 3 97 323-6Patient-derived xenografts recapitulate molecular features of human uveal melanomas.
Laurent C, Gentien D, Piperno-Neumann S, Némati F, Nicolas A, Tesson B, Desjardins L, Mariani P, Rapinat A, Sastre-Garau X, Couturier J, Hupé P, de Koning L, Dubois T, Roman-Roman S, Stern MH, Barillot E, Harbour JW, Saule S, Decaudin D, 2013 Jun Mol Oncol 3 7 625-36A role for Jag2 in promoting uveal melanoma dissemination and growth.
Asnaghi L, Handa JT, Merbs SL, Harbour JW, Eberhart CG, 2013 Jan Invest Ophthalmol Vis Sci 1 54 295-306Retinoblastoma protein prevents enteric nervous system defects and intestinal pseudo-obstruction.
Fu M, Landreville S, Agapova OA, Wiley LA, Shoykhet M, Harbour JW, Heuckeroth RO, 2013 Dec J Clin Invest 12 123 5152-64BAP1 deficiency causes loss of melanocytic cell identity in uveal melanoma.
Matatall KA, Agapova OA, Onken MD, Worley LA, Bowcock AM, Harbour JW, 2013 Aug BMC Cancer 13 371Impaired cholesterol efflux in senescent macrophages promotes age-related macular degeneration.
Sene A, Khan AA, Cox D, Nakamura RE, Santeford A, Kim BM, Sidhu R, Onken MD, Harbour JW, Hagbi-Levi S, Chowers I, Edwards PA, Baldan A, Parks JS, Ory DS, Apte RS, 2013 Apr Cell Metab 4 17 549-61Genomic, prognostic, and cell-signaling advances in uveal melanoma.
Harbour JW, 2013 Am Soc Clin Oncol Educ Book 388-91High throughput mass spectrometry-based mutation profiling of primary uveal melanoma.
Daniels AB, Lee JE, MacConaill LE, Palescandolo E, Van Hummelen P, Adams SM, DeAngelis MM, Hahn WC, Gragoudas ES, Harbour JW, Garraway LA, Kim IK, 2012 Oct Invest Ophthalmol Vis Sci 11 53 6991-6The genetics of uveal melanoma: an emerging framework for targeted therapy.
Harbour JW, 2012 Mar Pigment Cell Melanoma Res 2 25 171-81Histone deacetylase inhibitors induce growth arrest and differentiation in uveal melanoma.
Landreville S, Agapova OA, Matatall KA, Kneass ZT, Onken MD, Lee RS, Bowcock AM, Harbour JW, 2012 Jan Clin Cancer Res 2 18 408-16Notch signaling promotes growth and invasion in uveal melanoma.
Asnaghi L, Ebrahimi KB, Schreck KC, Bar EE, Coonfield ML, Bell WR, Handa J, Merbs SL, Harbour JW, Eberhart CG, 2012 Feb Clin Cancer Res 3 18 654-65Uveal melanoma: molecular pattern, clinical features, and radiation response.
Chappell MC, Char DH, Cole TB, Harbour JW, Mishra K, Weinberg VK, Phillips TL, 2012 Aug Am J Ophthalmol 2 154 227-232.e2Diagnostic testing and treatment choices in primary vitreoretinal lymphoma.
Rajagopal R, Harbour JW, 2011 Mar Retina 3 31 435-40ABCB1 identifies a subpopulation of uveal melanoma cells with high metastatic propensity.
Landreville S, Agapova OA, Kneass ZT, Salesse C, Harbour JW, 2011 Jun Pigment Cell Melanoma Res 3 24 430-7Association between gene expression profile, proliferation and metastasis in uveal melanoma.
Onken MD, Worley LA, Harbour JW, 2010 Sep Curr Eye Res 9 35 857-63A transformation in ocular oncology: from megacenter to multicenter.
Harbour JW, 2010 Mar Arch Ophthalmol 3 128 367-8Id2 deficiency promotes metastasis in a mouse model of ocular cancer.
Agapova OA, Person E, Harbour JW, 2010 Feb Clin Exp Metastasis 2 27 91-6Molecular prognostic testing and individualized patient care in uveal melanoma.
Harbour JW, 2009 Dec Am J Ophthalmol 6 148 823-9.e1Emerging insights into the molecular pathogenesis of uveal melanoma.
Landreville S, Agapova OA, Harbour JW, 2008 Oct Future Oncol 5 4 629-36Correlation study of benign cytomorphology and final clinical diagnosis.
Zhai J, Harbour JW, Smith ME, Dávila RM, 2008 Mar-Apr Acta Cytol 2 52 196-200Hepatic arterial chemoembolization for management of metastatic melanoma.
Sharma KV, Gould JE, Harbour JW, Linette GP, Pilgram TK, Dayani PN, Brown DB, 2008 Jan AJR Am J Roentgenol 1 190 99-104Tilting of radioactive plaques after initial accurate placement for treatment of uveal melanoma.
Almony A, Breit S, Zhao H, Garcia-Ramirez J, Mansur DB, Harbour JW, 2008 Jan Arch Ophthalmol 1 126 65-70Integrative genomic analysis of aneuploidy in uveal melanoma.
Ehlers JP, Worley L, Onken MD, Harbour JW, 2008 Jan Clin Cancer Res 1 14 115-22Treatment outcomes for primary intraocular lymphoma: implications for external beam radiotherapy.
Berenbom A, Davila RM, Lin HS, Harbour JW, 2007 Sep Eye (Lond) 9 21 1198-201Transcriptomic versus chromosomal prognostic markers and clinical outcome in uveal melanoma.
Worley LA, Onken MD, Person E, Robirds D, Branson J, Char DH, Perry A, Harbour JW, 2007 Mar Clin Cancer Res 5 13 1466-71Molecular prognostic testing in uveal melanoma: has it finally come of age?
Harbour JW, 2007 Aug Arch Ophthalmol 8 125 1122-3Rb at the interface between cell cycle and apoptotic decisions.
Delston RB, Harbour JW, 2006 Nov Curr Mol Med 7 6 713-8Prognostic testing in uveal melanoma by transcriptomic profiling of fine needle biopsy specimens.
Onken MD, Worley LA, Dávila RM, Char DH, Harbour JW, 2006 Nov J Mol Diagn 5 8 567-73Functional gene expression analysis uncovers phenotypic switch in aggressive uveal melanomas.
Onken MD, Ehlers JP, Worley LA, Makita J, Yokota Y, Harbour JW, 2006 May Cancer Res 9 66 4602-9Eye cancer: unique insights into oncogenesis: the Cogan Lecture.
Harbour JW, 2006 May Invest Ophthalmol Vis Sci 5 47 1736-45Lipid exudation following plaque radiotherapy for posterior uveal melanoma.
Mills MD, Harbour JW, 2006 Mar Am J Ophthalmol 3 141 594-595Fine needle aspiration biopsy with adjunct immunohistochemistry in intraocular tumor management.
Faulkner-Jones BE, Foster WJ, Harbour JW, Smith ME, Dávila RM, 2005 May-Jun Acta Cytol 3 49 297-308Functional analysis of the p53 pathway in response to ionizing radiation in uveal melanoma.
Sun Y, Tran BN, Worley LA, Delston RB, Harbour JW, 2005 May Invest Ophthalmol Vis Sci 5 46 1561-4DDEF1 is located in an amplified region of chromosome 8q and is overexpressed in uveal melanoma.
Ehlers JP, Worley L, Onken MD, Harbour JW, 2005 May Clin Cancer Res 10 11 3609-13For whom the bell tolls: susceptibility to common adult cancers in retinoblastoma survivors.
Kaye FJ, Harbour JW, 2004 Mar J Natl Cancer Inst 5 96 342-3Photodynamic therapy for choroidal metastasis from carcinoid tumor.
Harbour JW, 2004 Jun Am J Ophthalmol 6 137 1143-5Cytologic diagnosis of intraocular lymphoma in vitreous aspirates.
Farkas T, Harbour JW, Dávila RM, 2004 Jul-Aug Acta Cytol 4 48 487-91Association between choroidal pigmentation and posterior uveal melanoma in a white population.
Harbour JW, Brantley MA, Hollingsworth H, Gordon M, 2004 Jan Br J Ophthalmol 1 88 39-43Association between posterior uveal melanoma and iris freckles, iris naevi, and choroidal naevi.
Harbour JW, Brantley MA, Hollingsworth H, Gordon M, 2004 Jan Br J Ophthalmol 1 88 36-8Pars plana vitrectomy in eyes containing a treated posterior uveal melanoma.
Foster WJ, Harbour JW, Holekamp NM, Shah GK, Thomas MA, 2003 Sep Am J Ophthalmol 3 136 471-6Transpupillary thermotherapy versus plaque radiotherapy for suspected choroidal melanomas.
Harbour JW, Meredith TA, Thompson PA, Gordon ME, 2003 Nov Ophthalmology 11 110 2207-14; discussion 2215Distinct mechanisms for regulating the tumor suppressor and antiapoptotic functions of Rb.
Ma D, Zhou P, Harbour JW, 2003 May J Biol Chem 21 278 19358-66Ocular melanoma: a review and the relationship to cutaneous melanoma.
Hurst EA, Harbour JW, Cornelius LA, 2003 Aug Arch Dermatol 8 139 1067-73Transducible peptide therapy for uveal melanoma and retinoblastoma.
Harbour JW, Worley L, Ma D, Cohen M, 2002 Oct Arch Ophthalmol 10 120 1341-6Rate of resolution of exudative retinal detachment after plaque radiotherapy for uveal melanoma.
Harbour JW, Ahmad S, El-Bash M, 2002 Nov Arch Ophthalmol 11 120 1463-9Altered expression of Rb and p53 in uveal melanomas following plaque radiotherapy.
Brantley MA, Worley L, Harbour JW, 2002 Feb Am J Ophthalmol 2 133 242-8Photodynamic therapy for circumscribed choroidal hemangioma.
Sheidow TG, Harbour JW, 2002 Aug Can J Ophthalmol 5 37 314-7Langerhans cell histiocytosis diagnosed by fine needle biopsy.
Harbour JW, Char DH, Ljung BM, Luna-Fineman S, 1997 Sep Arch Ophthalmol 9 115 1212-3Pars plana vitrectomy in the management of phakic and pseudophakic malignant glaucoma.
Harbour JW, Rubsamen PE, Palmberg P, 1996 Sep Arch Ophthalmol 9 114 1073-8Local carboplatin therapy in transgenic murine retinoblastoma.
Harbour JW, Murray TG, Hamasaki D, Cicciarelli N, Hernández E, Smith B, Windle J, O'Brien JM, 1996 Aug Invest Ophthalmol Vis Sci 9 37 1892-8Pars plana vitrectomy for chronic pseudophakic cystoid macular edema.
Harbour JW, Smiddy WE, Rubsamen PE, Murray TG, Davis JL, Flynn HW, 1995 Sep Am J Ophthalmol 3 120 302-7Initial management and follow-up of melanocytic iris tumors.
Harbour JW, Augsburger JJ, Eagle RC, 1995 Dec Ophthalmology 12 102 1987-93Uveal metastasis from carcinoid tumor. Clinical observations in nine cases.
Harbour JW, De Potter P, Shields CL, Shields JA, 1994 Jun Ophthalmology 6 101 1084-90Clivus chordoma: a report of 12 recent cases and review of the literature.
Harbour JW, Lawton MT, Criscuolo GR, Holliday MJ, Mattox DE, Long DM, 1991 Skull Base Surg 4 1 200-6Expression in lung cancer of a transcribed sequence at the DNF15S2 locus at chromosome 3P21.
Harbour JW, Lai SL, Gazdar AF, Minna JD, Kaye FJ, 1990 Jan-Feb Anticancer Res 1 10 23-7Loss of heterozygosity in a gene coding for a thyroid hormone receptor in lung cancers.
Leduc F, Brauch H, Hajj C, Dobrovic A, Kaye F, Gazdar A, Harbour JW, Pettengill OS, Sorenson GD, van den Berg A, 1989 Feb Am J Hum Genet 2 44 282-7Abnormalities in structure and expression of the human retinoblastoma gene in SCLC.
Harbour JW, Lai SL, Whang-Peng J, Gazdar AF, Minna JD, Kaye FJ, 1988 Jul Science 4863 241 353-7